Nanox Gains FDA Clearance for TAP2D, Advancing U.S. Tomosynthesis Strategy
Event summary
- Nanox received FDA 510(k) clearance for TAP2D, a cloud-enabled image enhancement capability for its Nanox.ARC and Nanox.ARC X systems on February 3, 2026.
- TAP2D generates a 2D image from a tomosynthesis scan, providing both 3D and 2D views without additional radiation exposure.
- The clearance supports Nanox's goal of removing adjunctive use requirements in the U.S., aligning with its CE Mark certification in Europe.
- Existing Nanox.ARC systems can receive software upgrades remotely following regulatory clearances.
The big picture
Nanox's FDA clearance for TAP2D is a critical step in its strategy to position its tomosynthesis systems as primary diagnostic tools in the U.S. This aligns with broader industry trends toward preventive healthcare and the integration of AI-driven analytics in medical imaging. The company's end-to-end platform approach, combining hardware, software, and cloud services, aims to lower barriers to adoption and improve access to high-quality imaging globally.
What we're watching
- Regulatory Strategy
- How Nanox will leverage this clearance to achieve standalone primary imaging status in the U.S., mirroring its European success.
- Market Adoption
- The pace at which existing Nanox.ARC installations will integrate TAP2D and other upcoming software enhancements.
- Competitive Positioning
- Whether Nanox can sustain its cost and radiation dose advantages against traditional imaging systems with these innovations.
Related topics